LPL Financial LLC Sells 1,527 Shares of VanEck Biotech ETF (NASDAQ:BBH)

LPL Financial LLC reduced its holdings in VanEck Biotech ETF (NASDAQ:BBH) by 5.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 24,747 shares of the company’s stock after selling 1,527 shares during the period. LPL Financial LLC’s holdings in VanEck Biotech ETF were worth $3,885,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of BBH. Farther Finance Advisors LLC acquired a new position in shares of VanEck Biotech ETF during the fourth quarter valued at about $32,000. SBI Securities Co. Ltd. acquired a new position in VanEck Biotech ETF in the 4th quarter valued at approximately $81,000. Wilmington Savings Fund Society FSB acquired a new position in VanEck Biotech ETF in the 3rd quarter valued at approximately $166,000. Commonwealth Retirement Investments LLC bought a new stake in shares of VanEck Biotech ETF in the 4th quarter worth approximately $215,000. Finally, Independent Advisor Alliance acquired a new stake in shares of VanEck Biotech ETF during the 4th quarter worth approximately $250,000. 32.05% of the stock is currently owned by institutional investors and hedge funds.

VanEck Biotech ETF Trading Down 4.6 %

Shares of NASDAQ BBH opened at $140.59 on Friday. The firm has a market capitalization of $327.57 million, a price-to-earnings ratio of 29.88 and a beta of 0.85. VanEck Biotech ETF has a one year low of $135.34 and a one year high of $183.64. The business has a fifty day simple moving average of $159.61 and a 200 day simple moving average of $164.18.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.